<code id='19F1B1707A'></code><style id='19F1B1707A'></style>
    • <acronym id='19F1B1707A'></acronym>
      <center id='19F1B1707A'><center id='19F1B1707A'><tfoot id='19F1B1707A'></tfoot></center><abbr id='19F1B1707A'><dir id='19F1B1707A'><tfoot id='19F1B1707A'></tfoot><noframes id='19F1B1707A'>

    • <optgroup id='19F1B1707A'><strike id='19F1B1707A'><sup id='19F1B1707A'></sup></strike><code id='19F1B1707A'></code></optgroup>
        1. <b id='19F1B1707A'><label id='19F1B1707A'><select id='19F1B1707A'><dt id='19F1B1707A'><span id='19F1B1707A'></span></dt></select></label></b><u id='19F1B1707A'></u>
          <i id='19F1B1707A'><strike id='19F1B1707A'><tt id='19F1B1707A'><pre id='19F1B1707A'></pre></tt></strike></i>

          leisure time

          leisure time

          author:explore    Page View:5
          Adobe

          By some measures, private equity investment lagged in 2023, a year marked by growing distress and high-profile downfalls among private equity-backed health care companies.

          Even so, three sectors still managed to see strong deal flow and prices: med spa, cardiology, and clinical trial sites, according to a new PitchBook report analyzing private equity investments in health care services in 2023. Each of the three niches continue to generate buzz among investors, even as other areas fizzle.

          advertisement

          It’s not that those three industries are perfect fits for private equity, it’s that the more obvious areas like autism therapists and physician practices are struggling with high interest rates and regulatory scrutiny, said Rebecca Springer, PitchBook’s lead health care analyst.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          Susan Tousi leaves Illumina to head cancer liquid biopsy startup
          Susan Tousi leaves Illumina to head cancer liquid biopsy startup

          SusanTousiisleavingIlluminatobecomeCEOofcancerliquid-biopsystartupDelfi.NasdaqDelfiDiagnostics,astar

          read more
          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more

          Medicare’s new pay boost for primary care is angering specialists

          AdobeWASHINGTON—DoctorsarestaringdownacuttotheirMedicarepaynextyear,andwhilethenewshasunitedtheminou